Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of CAL02 Administered Intravenously in Addition to Standard of Care in Subjects With Severe Community-Acquired Bacterial Pneumonia (SCABP)
NCT05776004 is registered in ClinicalTrials.gov with Eagle Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of CAL02 Administered Intravenously in Addition to Standard of Care in Subjects With Severe Community-Acquired Bacterial Pneumonia (SCABP)
- Lead sponsor
- Eagle Pharmaceuticals, Inc.
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- July 22, 2023
- Completion date
- September 7, 2026
- Enrollment
- 276 (estimated)
- Sites
- 90
Conditions
As the registry lists them; a condition with its own page is linked.